← All stocks

Spyre Therapeutics, Inc.

SYRE Mostly scheduled
CIK 0001636282 #969 in the set updated 17 Sep 2026
Bought (120 mo)
$4.00M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$439.21M
$19.83M on a plan · $417.13M straight out of an exercise
Sold at will
$2.25M
9 of 90 sales
Net
−$435.21M
+$1.75M against sales at will

By person

17 insiders · 147 transactions
74.2×

Cameron Turtle holds 74.2 times base salary in stock. $49.37M of shares against $665.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Cameron Turtle last reported holding, valued at $89.35, the price Common Stock was last bought or sold at on the open market here, on 2 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Fairmount Funds Management LLC entity
Director
$399.66M (1) scheduled
−$399.66M
0
0.0000%
$0.00
Turtle Cameron
Chief Executive Officer
$9.99M (34) scheduled
−$9.99M
552,540
0.6266%
$49.37M
+2,231%
HENDERSON MICHAEL THOMAS
Director
$7.95M (5) scheduled
−$7.95M
68,606
0.0778%
$6.13M
Burrows Scott L
Chief Financial Officer
$7.68M (22) scheduled
−$7.68M
79,762
0.0905%
$7.13M
Sloan Sheldon
Chief Medical Officer
$7.35M (11) scheduled
−$7.35M
0
0.0000%
$0.00
Albers Jeffrey W.
Director
$2.66M (5) scheduled
−$2.66M
9,360
0.0106%
$836.32K
−72.8%
King-Jones Heidy
See Remarks
$2.48M (5) scheduled
−$2.48M
2,845
0.0032%
$254.20K
0.0%
Quinn Anthony G.
President & CEO
$2.10M (25)
+$2.10M
550,540
0.6244%
$49.19M
Novartis Bioventures Ltd entity
10% owner
$1.37M (5)
−$1.37M
2,175,314
2.47%
$194.36M
−5.9%
Alspaugh Jonathan
President and CFO
$604.66K (5)
+$604.66K
165,372
0.1876%
$14.78M
ORBIMED ADVISORS LLC entity
10% owner
$563.88K (3)
+$563.88K
1,469,524
1.67%
$131.30M
+8.0%
Shanafelt Armen
Director
$549.69K (3)
+$549.69K
150,000
0.1701%
$13.40M
York Charles N II
Chief Financial Officer and VP
$108.25K (5)
+$108.25K
34,787
0.0395%
$3.11M
+221.3%
Schuchart Aaron
Chief Business Officer
$57.01K (2)
−$57.01K
2,500
0.0028%
$223.38K
Souza Marcio
Director
$50.47K (1)
+$50.47K
90,000
0.1021%
$8.04M
Hanley Jr. Michael Conick
Chief Business Officer
$20.02K (1)
+$20.02K
36,200
0.0411%
$3.23M
+352.5%
GEORGIOU GEORGE
Director
175,861
0.1994%
$15.71M
+26.9%
Insider
Date
Role
Action
Shares
Price
Amount
Burrows Scott L
2 Sep 2025
Chief Financial Officer
Sell
18,428
$16.26
$299.64K
Burrows Scott L
3 Sep 2024
Chief Financial Officer
Sell
18,531
$28.17
$522.07K
Schuchart Aaron
27 Sep 2018
Chief Business Officer
Sell
5,900
$9.50
$56.05K
Schuchart Aaron
27 Sep 2018
Chief Business Officer
Sell
100
$9.55
$955.00
Novartis Bioventures Ltd
11 May 2018
10% owner
Sell
19,550
$10.06
$196.67K
Novartis Bioventures Ltd
10 May 2018
10% owner
Sell
22,725
$10.13
$230.20K
Novartis Bioventures Ltd
9 May 2018
10% owner
Sell
51,230
$10.11
$517.94K
Novartis Bioventures Ltd
8 May 2018
10% owner
Sell
26,557
$10.03
$266.37K
Novartis Bioventures Ltd
7 May 2018
10% owner
Sell
15,548
$10.11
$157.19K

What was left out

Form 4 filings counted 202
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 0
Joint filings 14
Sales on a Rule 10b5-1 plan 42
Sales straight out of an exercise 39
Sales at will 9
Transactions with no price 0
Shares from compensation/vesting 13,522,780
Sales filed before the plan box existed 7
History held since 16 Feb 2017